XML 36 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible assets
 11 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible assets Intangible assets
December 31, 2019January 31, 2019January 31, 2018
(in thousands)
Utrophin program acquired$4,379 $4,358 $4,708 
Discuva platform acquired14,070 14,002 15,125 
Option over non-financial assets881 877 947 
Other patents and licenses432 291 376 
     Total intangible assets, gross19,762 19,528 21,156 
Less: Accumulated amortization2,263 1,255 198 
         Impairment4,379 4,358 — 
Intangible assets, net of accumulated amortization$13,120 $13,915 $20,958 


As a result of the Group's decision in June 2018 to discontinue development of ezutromid, management concluded that this was an indication of intangible assets impairment and hence reviewed the intangible assets associated with the acquisition of MuOx Limited which related to the utrophin program acquired. Based on this review, an intangible assets impairment charge of $4.4 million related to the utrophin program acquired was recognized during the year ended January 31, 2019. See note 10 for details.

Amortization expense was $1.0 million, $1.1 million and $0.1 million, for the periods ended December 31, 2019, January 31, 2019 and 2018, respectively.

Estimated future amortization expense related to intangible assets held at December 31, 2019 and January 31, 2019 is as follows:


December 31, 2019
January 31, 2019
(in thousands)
2020
$1,083 $1,150 
2021
$1,048 $1,133 
2022
$1,048 $1,102 
2023
$1,048 $1,102 
2024
$1,048 $1,102